Abstract: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies, and is also the fourth most common cancer worldwide with around 700,000 new cases each year. Currently, first line chemotherapeutic drugs used for HCC include fluorouracil, cisplatin, doxorubicin, paclitaxel and mitomycin, but most of these are non-selective cytotoxic molecules with significant side effects. Sorafenib is the only approved targeted therapy by the U.S. Food and Drug Administration for HCC treatment, but patients suffer from various kinds of adverse effects, including hypertension. The signal-transducer-and-activator-of-transcription 3 (STAT3) protein, as a member of STATs transcription factor family, has been implicated in signal transduction by various cytokines, growth factors and oncoproteins. In normal cells, STAT3 activation is strictly controlled to prevent unscheduled gene regulation, whereas constitutively activated STAT3 is found to participate in oncogenesis through upregulation of genes encoding apoptosis inhibitors, cell cycle regulators and inducers of angiogenesis. Thus, pharmacologically safe and effective agents that can block STAT3 activation have the potential both for prevention and treatment of HCC. In the present review, we discuss the potential role of STAT3 signaling cascade and its interacting partners in the initiation of HCC and also analyze the role of various STAT3 regulated genes in HCC progression, survival, invasion and angiogenesis. Please purchase PDF Split-Merge on www.verypdf.com to remove this watermark. Please purchase PDF Split-Merge on www.verypdf.com to remove this watermark.
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SUMMARY
Aberrant activation of signal transducer and activators of transcription 3 (STAT3) is frequently encountered and promotes proliferation, survival, invasion, metastasis and angiogenesis in hepatocellular carcinoma (HCC). In the present study, we investigated whether emodin mediates its effect through interference with the STAT3 activation pathway in HCC. The effect emodin on STAT3 activation, associated protein kinases, cellular proliferation and apoptosis was investigated. The in vivo effect of emodin on the orthotopic mice model was also examined. We found that In the present report, we investigated the potential of emodin to enhance apoptosis induced by TRAIL in HCC cells. As observed by accumulation of the membrane phospholipid phosphatidylserine, intracellular esterase activity, and activation of caspase-8, -9, and -3, we found that emodin can potentiate TRAIL-induced apoptosis in HCC cells. When investigated for the mechanism(s), we observed that emodin can downregulate the expression of various cell survival proteins, and induced the cell surface expression of both TRAIL receptors, death receptors (DR) 4 and 5. Knockdown of either receptor by small interfering RNA reduced the apoptosis induced by emodin alone and in combination with TRAIL. In addition, emodin increased the expression of CHOP proteins. Knockdown of CHOP by siRNA decreased the induction of emodin-induced DR5 expression and apoptosis. We also noticed that emodin-induced induction of DR5 was mediated through generation of reactive oxygen species (ROS), as N-acetylcysteine blocked the induction of DR5 and the induction of apoptosis by emodin. Overall, our experimental results clearly indicate that emodin can indeed potentiate TRAIL-induced apoptosis through downregulation of antiapoptotic proteins, increased expression of apoptotic proteins, and ROS mediated upregulation of death receptors in HCC cells.
role in the process of invasion and metastasis that accounts for more than 80% of deaths in hepatocellular carcinoma patients. Thus, identification of novel drugs that can downregulate CXCR4 expression and function have a great potential in the treatment of metastatic hepatocellular carcinoma. In the present report, we investigated an anthraquinone derivative, emodin for its ability to modulate CXCR4 expression and function and found that emodin downregulated the expression of CXCR4 in hepatocellular carcinoma cell lines in a dose-and time-dependent manner. Neither proteasome inhibitor nor lysosomal stabilization had any effect on emodin-induced decrease in CXCR4 expression. When investigated for the molecular mechanism(s), it was observed that the downregulation of CXCR4 was due to transcriptional regulation as indicated by downregulation of mRNA expression, inhibition of NF-NB activation, and modulation of chromatin immunoprecipitation activity. Modulation of CXCR4 expression by emodin further correlated with the inhibition of CXCL12-induced migration and invasion in hepatocellular carcinoma cell lines. In addition, abrogation of the expression of CXCR4 by emodin was also found in liver tissues from orthotopic animal model. Overall, our results show that emodin is a novel blocker of CXCR4 expression and, thus, has the potential to suppress the invasion and metastasis of hepatocellular carcinoma.
